Cargando…

Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

The treatment of cancer patients with immune checkpoint inhibitors (ICI) (anti-CTLA-4, anti-PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt been a significant breakthrough in the field of oncology in recent years and constitutes a major step forward as a novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wojtukiewicz, Marek Z., Rek, Magdalena M., Karpowicz, Kamil, Górska, Maria, Polityńska, Barbara, Wojtukiewicz, Anna M., Moniuszko, Marcin, Radziwon, Piotr, Tucker, Stephanie C., Honn, Kenneth V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556173/ https://www.ncbi.nlm.nih.gov/pubmed/34236546 http://dx.doi.org/10.1007/s10555-021-09976-0

Ejemplares similares

Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2020)

Heterogeneous Expression of Proangiogenic and Coagulation Proteins in Gliomas of Different Histopathological Grade
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2021)

Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2021)

Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions
por: Grubczak, Kamil, et al.
Publicado: (2021)

Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2022)

Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2019)

Ozonation of Whole Blood Results in an Increased Release of Microparticles from Blood Cells
por: Boczkowska-Radziwon, Barbara, et al.
Publicado: (2022)

Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2020)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
por: Le Mercier, Isabelle, et al.
Publicado: (2015)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Protease-activated receptors (PARs)—biology and role in cancer invasion and metastasis
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2015)

Platelets and cancer angiogenesis nexus
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2017)

Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2017)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds
por: Li, Wei, et al.
Publicado: (2019)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia
por: Broglie, Larisa, et al.
Publicado: (2019)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma
por: Goto, Megumi, et al.
Publicado: (2019)

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
por: Porcellato, Ilaria, et al.
Publicado: (2021)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
por: Lambertini, Matteo, et al.
Publicado: (2019)

PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy
por: Delmas, Dominique, et al.
Publicado: (2021)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study
por: Zhao, Xiaoqin, et al.
Publicado: (2018)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
por: Gu, Lihu, et al.
Publicado: (2019)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
por: Puri, Sonam, et al.
Publicado: (2020)

Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer
por: Świderska, Janina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_segeic17kt8mo8a5gu7fn7ve09